Kaya Holdings, Inc.

What they do

Kaya Holdings operates through three subsidiaries: Kaya Brands International (KBI) for medical cannabis expansion overseas, Fifth Dimension Therapeutics (FDT) for psychedelic treatments, and Kaya Crypto Operations for a planned digital assets treasury strategy. The company's main revenue-generating activity in recent quarters has been psilocybin services at its Portland, Oregon facility, which ceased operations on October 31, 2025. KBI holds a cannabis cultivation and processing license in Greece but the project remains unfunded and incomplete.

Revenue drivers

• Psilocybin treatments — FDT provided psilocybin treatments at its Portland facility from September 2024 to October 31, 2025, generating the majority of recent quarterly revenue ($5,408 in Q3 2025).
• Cannabis projects (KBI) — KBI's Greek Epidaurus project is designed for cultivation and EU-GMP extraction but has not generated revenue; it awaits project financing.
• Future crypto operations — Kaya Crypto Operations, formed October 20, 2025, has no revenue yet; management is in discussions to develop a DATCO strategy.

Recent performance

Revenue fell from $889,899 in 2021 to $7,134 in 2024. Quarterly revenue for Q3 2025 was $5,408, down from $7,052 in Q1 2025 and $10,097 in Q2 2025. The company incurred a net loss from continuing operations of $8,591,465 in Q3 2025. As of September 30, 2025, total assets were $199,358, cash was $26,087, and shareholder equity was negative $547,443.

Strategy

Management is pivoting to a Digital Assets Treasury Company (DATCO) strategy through Kaya Crypto Operations, seeking joint ventures with top-200 cryptocurrencies, likely on Solana, Ethereum, or Polygon networks. They are also exploring partnerships with pharmaceutical companies for psilocybin trials using their OHA license. The Portland lease was terminated, and clients are now being placed at local service centers. Discussions involve Conduit Advisors and Greentree Financial Group; no definitive agreement has been signed.

Risks

• Going concern — Substantial doubt about the company's ability to continue as a going concern, with negative equity and minimal cash.
• Revenue collapse — Annual revenue dropped from $1.0M in 2020 to $7,134 in 2024, and quarterly revenue remains under $11,000.
• Unfunded Greek project — The Epidaurus Project remains incomplete and awaits financing, with no revenue potential until completed.
• Crypto venture uncertainty — The DATCO strategy is in early discussions with no definitive agreements, and the company has no experience in cryptocurrency operations.

Outlook

Management plans to continue pursuing crypto treasury joint ventures and to leverage the OHA psilocybin license for pharmaceutical collaborations. The company expects to rely on external funding to complete the Greek project and support operations. No specific revenue guidance was provided.